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Abstract
Background: Measurement of serum concentrations of insulin-like growth factor
(IGF)-1 is used to diagnose acromegaly in cats.
Hypothesis: Changes of body weight do not affect serum concentrations of IGF-1
in cats.
Animals: Ten healthy purpose-bred cats.
Methods: Prospective study. In lean cats, food availability was stepwise increased
during the first week and given ad libitum for a total of 40 weeks to increase their
body weight. From week 41 to week 60, food access was limited to reach a weight
loss of 1% to 2% each week. Measurement of IGF-1 was performed at week 0, 16,
40, and 60. Insulin-like growth factor-1 was measured by radioimmunoassay. Body
weight and IGF-1 were compared among the 4 time points.
Results: Bodyweight increasedby44%fromweek0 (4.5 ± 0.4kg) toweek40 (6.5 ± 1.2kg)
(P < .001) and decreased by 25% fromweek 40 to week 60 (4.9 ± 0.7 kg) (P < .001). Serum
IGF-1 concentrations did not differ during the study period (week 0, 16, 40, 60: 500 ± 188,
479 ± 247, 470 ± 184, 435 ± 154 ng/mL, respectively; P = .38). Correlations with body
weightwere not observed.
Conclusions and Clinical Importance: Insulin-like growth factor-1 might not be
influenced by changes of body weight in healthy cats, possibly suggesting that the
latter is unimportant when interpreting IGF-1 results in this species.
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1 | INTRODUCTION
Insulin like growth factor-1 (IGF-1) is a single chain polypeptide which
acts in synergy with growth hormone (GH) to mediate its anabolic
effects.1,2 Insulin-like growth factor-1 is mostly secreted by the liver
under GH induction.3 Insulin, through an upregulation of hepatic GH
receptors, increases IGF-1 secretion.4 Serum IGF-1 concentration
reflects GH activity during the 24 hours and its measurement is
employed as diagnostic test to assess GH disorders in humans.5,6
Circulating IGF-1 consists of free IGF-1, the active form of the hor-
mone, and IGF-1 bound to specific proteins (ie, IGF-1 binding proteins
[IGFBPs]).7 Obese people have lower circulating IGFBPs leading toAbbreviations: IGF-1, insulin-like growth factor-1; IGFBPs, IGF-1 binding proteins.
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increased availability of free IGF-1, which causes a negative feedback
on GH; the drop of GH decreases IGF-1 release.8,9
In cats, IGF-1 measurement is used to diagnose acromegaly, a dis-
ease characterized by aberrant GH production because of pituitary ade-
noma.10 Other than acromegaly different conditions influence IGF-1
activity in cats. Reduced concentrations of circulating IGF-1 occur in
newly diagnosed diabetic cats before the beginning of treatment because
of the lack of insulin upregulation of hepatic GH receptors.11 Decreased
IGF-1 concentrations in cats also occur with lymphoma, hyperthyroidism
and with aging.11-13 Information about the effects of body weight
change on circulating IGF-1 levels is conflicting. A lack of correlation
between body weight and IGF-1 is reported in healthy and in diabetic
cats,11 while other studies report a positive correlation in healthy cats
and in cats with different diseases13; IGF-1 increases by 38% for each
kilogram increase in body weight. Furthermore, after a 42% daily energy
intake restriction, serum IGF-1 and body weight significantly decreased
in non-obese cats, whereas IGF-1 concentrations increase in obese cats
after weight loss.14,15 Insulin-like growth factor-1 binding proteins can
interfere with IGF-1 measurement resulting in falsely increased or
decreased concentrations, depending on the assay.12,13
In light of the conflicting results reported for IGF-1 concentrations
in relation to body weight, the aim of this prospective study was to eval-
uate the effect of body weight changes imposed by overfeeding and
food restriction, respectively, on circulating IGF-1 in healthy cats.
2 | MATERIALS AND METHODS
2.1 | Animals
The study protocol was approved by the Veterinary Office of the Can-
ton of Zurich and conducted in accordance with guidelines established
by the Animal Welfare Act of Switzerland (permission number: 118/16).
Ten healthy purpose-bred male castrated domestic short hair cats were
used for the study. Median age was 6.5 years (range, 6.3-6.6). Initially,
median body weight was 4.5 kg (range, 3.6-5.1) and body condition
score, as assessed on a 9-point scale,16 was 5 for all cats. The cats were
group housed in the animal research facility of the Vetsuisse Faculty,
University of Zurich (Switzerland).
2.2 | Feeding plan
The study period was 60 weeks. Throughout the investigation, the
10 cats were fed a commercial dry food (Science Diet Adult Optimal
Care, Hill's Pet Nutrition, Topeka, Kansas). General conditions were
monitored on a daily basis and body weight and physical examination
were assessed weekly in all cats. During the first week each cat was
fed separately. To avoid vomiting because of overeating the daily
ration was increased stepwise. In particular, during the first 2 days
each cat was fed the resting energy requirement (RER)17 increased by
50%. The daily RER was doubled on day 3 and 4. On day 5 and 6, the
daily ration was increased to 2.5-fold of the RER. From day 7, if cats
did not vomit, they were housed in a single group and the food was
provided ad libitum until week 40. Body condition score was noted at
the end of week 40.
From week 41, the cats were fed separately and the amount of
food was reduced stepwise to reach the daily RER, mirroring the
approach used during the first week. Thereafter, body weight was
assessed every week and food access was individually limited to
achieve a weight loss of around 1% to 2% each week, until week 60.
Body weights were measured in week 0, 16, 40, and 60.
2.3 | Sampling
At week 0, 16, 40, and 60, cats underwent a physical examination and
were sedated with 0.1 mg/kg of midazolam (Dormicum, Roche AG,
Basel, Switzerland) and 10 mg/kg of ketamine (Keta-S, Graeub, Bern,
Switzerland) for blood sampling. Blood was collected from the jugular
vein. Samples for cell blood counts and biochemical profiles were ana-
lyzed by standard methods in the clinical laboratory of the faculty.
Serum samples were stored at −80C to determine IGF-1 concentra-
tions in batch.
2.4 | Insulin-like growth factor-1 measurement
Serum IGF-1 was measured by radioimmunoassay (Mediagnost
IGF-R20, Mediagnost, Reutlingen, Germany) at the NationWide Special-
ist Laboratories, Pampisford, Cambridge, UK. Briefly, 10 μL of cat serum
was diluted in 1 mL of acidic buffer solution (pH <3.1) to dissociate
IGF-1 from IGFBPs. Then, an IGF-1 anti-rabbit polyclonal first antibody
with IGF-2 excess was diluted in a buffer able to neutralize the acidic
sample (pH 7). The IGF-2 excess binds to IGFBPs while the free IGF-1 is
then measurable; with this procedure IGFBPs interference was neutral-
ized by IGF-2. Thereafter, the sample was further processed using radio-
immunoassay and a second anti-rabbit polyclonal antibody for IGF-1.
Sensitivity of radioimmunoassay for IGF-1 was 0.02 to 0.109 μg/L and
no cross reactivity with IGF-2 was documented (ie, 0.1%). Intra-assay
variability was 4.8% (range, 1.0%-16.1%) and inter-assay variability was
5.1% (range, 4.5%-6.0%), as reported by the laboratory. Further assay
validation was achieved in cats by other authors.18
2.5 | Statistical analysis
Data were tested for Gaussian distribution with Shapiro-Wilk normal-
ity test; if non-normally distributed, they were log-transformed. Time
points were compared for body weight and IGF-1. Comparisons were
performed with 1-way analysis of variance for repeated measures
followed by Tukey's multiple comparisons test. Each P-value was
adjusted to account for multiple comparisons. In addition, at each time
point, correlations between body weight and IGF-1 were assessed
with Pearson correlation coefficients. Commercial software was used
for statistical analysis (GraphPad Prism 7.0, San Diego, California).
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3 | RESULTS
During the study period, no cat had diarrhea but 7 of the 10 cats
vomited on 1 to 2 episodes. Vomiting was assumed to be because of
fast eating and overeating and in all cases was self-limiting; medical
treatment was not necessary. At week 40, 1 cat reached a body con-
dition score of 7/9, 4 cats 8/9 and 5 cats 9/9. Body weight and IGF-1
concentrations at each time point are reported in Table 1. Body
weight significantly changed during the study period (P < .001)
(Figure 1). In particular, average body weight increased by 44% from
week 0 to week 40 and decreased by 24.7% from week 40 to week
60; of note, body weight at week 60 was still higher than at week
0 by 8.4%. Serum concentrations of IGF-1 did not differ during the
study period (P = .38) (Figure 2); none of the IGF-1 measurements
was >1000 ng/mL, which is the threshold commonly reported for
acromegaly,18 at any time point. Correlations between body weight
and IGF-1 were not observed (week 0: r = 0.531, 95% CI = −0.148 to
0.870, P = .11; week 16: r = 0.351, 95% CI = −0.357 to 0.803, P = .32;
week 40: r = 0.622, 95% CI = −0.011 to 0.899, P = .06; week 60:
r = 0.384, 95% CI = −0.323 to 0.816, P = .27).
Among blood work variables, during the study serum cholesterol
and triglycerides concentrations were increased above the reference
interval in 5 cats and 1, respectively. The remaining of the biochemical
profile and cell blood counts was within the reference interval.
4 | DISCUSSION
The present study shows that an increase of body weight followed by
its partial reduction did not affect serum IGF-1 concentrations in
healthy cats. In addition, there was no correlation between body
weight and IGF-1 before and after weight gain. These results confirm
a previous study where correlations between body weight and serum
IGF-1 concentrations were not documented in 18 healthy cats.11 Nev-
ertheless, contrasting results have been reported between body
weight and serum IGF-1 in cats.13-15 In particular, in a recent investi-
gation assessing circulating IGF-1 in 55 healthy cats and in 10 cats
with a variety of diseases, a positive correlation with body weight was
observed; in the same study no longitudinal assessment of IGF-1 and
body weight was performed to provide more information about their
relationship.13 In humans no correlation was identified between IGF-1
concentrations and body weight, while IGF-1 was negatively corre-
lated to body mass index, a parameter used to assess the nutritional
status.19,20 It was assumed that obesity lowers circulating IGFBPs,
leading to a decrease of IGF-1.8,9 Unfortunately, details regarding the
nutritional status of the cats enrolled in the previous studies were
scant to gain further insights.
In cats, body condition score is used to assess the nutritional sta-
tus and reliably semiquantifies the body fat percent.16,21 In the pre-
sent series, the 10 cats had a score of 5/9 at the study beginning
which increased to at least 7/9 at the end of the ad libitum period in
all, while IGF-1 concentrations did not change, suggesting that IGF-1
is not influenced by augmenting body fat in this species.
TABLE 1 Mean, standard deviation, and range of body weight and of serum concentrations of IGF-1, in the 10 healthy cats during the study
period
Week 0 Week 16 Week 40 Week 60
Body weight (kg) 4.5 ± 0.4 (3.6-5.1) 6.2 ± 1.3 (4.2-7.8) 6.5 ± 1.2 (4.3-8.7) 4.9 ± 0.7 (3.4-6.1)
IGF-1 (ng/mL) 500 ± 188 (297-841) 479 ± 247 (257-926) 470 ± 184 (318-904) 435 ± 154 (288-796)
F IGURE 1 Before and after dot plot of body weight in the
10 healthy cats during the study period. A solid line connects values
recorded in the same cat. Significant differences between time points
are reported
F IGURE 2 Before and after dot plot of serum IGF-1
concentrations in the 10 healthy cats during the study period. A solid
line connects values recorded in the same cat. No significant
differences were observed between time points
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In the present cats, food availability was gradually reduced from
week 41 to week 60 to achieve weight loss. Despite the significant
decrease in body weight, no change in IGF-1 concentrations was
observed. A previous study evaluated the effects of weight loss in
obese cats and it was reported that weight loss was associated to an
increase of IGF-1 compared to baseline.15 Because obese cats have
insulin resistance and because of the permissive role of insulin on
IGF-1 release, the authors assumed that improved insulin sensitivity
after weight loss explained the increase in IGF-1.15 Despite body
weight reduction, our cats at week 60 were still heavier compared to
week 0. Hence, we cannot exclude that insulin resistance was still pre-
sent impeding an increase of IGF-1. Another possible explanation for
the difference is represented by the diet used in the studies; in partic-
ular, the present cats received a maintenance diet while in the former
study a high-protein diet was given.15 A study in pigs reported that
high-protein diet increased hepatic IGF-1 gene expression with conse-
quent increase in circulating IGF-1.22 Conversely, in humans low-
protein diet increased serum IGFBPs, which in turn decreased IGF-1
concentrations.23 Hence, further studies are needed to assess the
relationship between diet proteins and circulating IGF-1 in cats.
Of note, in 1 study assessing the effect of restricting the daily
energy ration of healthy lean cats to 56% and to 42% during 2 weeks,
it was found that body weight decreased in both cases whereas IGF-1
concentrations decreased only in the latter.14 Similar to cats, different
studies in humans reported that weight loss is associated with IGF-1
reduction only when energy intake is below 50% of the daily
ration.24-28 Therefore, we hypothesize that energy restriction to
<50% daily ration more than body weight variation affects IGF-1 con-
centrations in cats.
The study has some limitations, particularly the fact that IGF-1
concentrations were measured without taking into account the poten-
tial bias of IGFBPs. In addition, it cannot be excluded that IGF-1 con-
centrations would have required longer to increase or decrease after
changes in body weight, despite the study design spanned over sev-
eral months. A positive correlation between IGF-1 and body weight
was not observed at any time point. It is possible that with a larger
number of cats and wider range of body weights for each body condi-
tion score, positive correlations would have been identified. Of note,
with a statistical power of 0.8 the sample size of 10 cats reached sig-
nificance with a correlation coefficient of 0.800. Despite correlation
coefficients are usually lower in clinical studies, the present investiga-
tion was based on an obesity model in healthy cats allowing to limit
the confounders and, possibly, increasing the chance of a high correla-
tion coefficient.
Insulin-like growth factor-1 measurements were relatively high
in 3 cats (ie, >800 ng/mL), which might be suspicious of acromeg-
aly.18 One of them had concentrations >800 ng/mL in 3 of the
4 measurements, while 2 only once. Whether this suggests an early
stage of acromegaly, in particular in the former cat, is unclear.
Nonetheless, after 2 years from the experiment, the 3 cats were
still in good health and none showed clinical signs associated with
acromegaly.
In conclusion, circulating IGF-1 might not be influenced by body
weight increase and by its partial decrease in healthy cats, possibly
suggesting that body weight is not important when interpreting IGF-1
results in this species.
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